First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study

Table 4 Toxic effects in each cohort

	Methotrexate (n = 52)				Teniposide (n = 33)				P value
	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	P value
Neutropenia	12 (23.1%)	5 (9.6%)	10 (19.2)	0	6 (18.2%)	6 (18.2%)	8 (24.2%)	0	0.325
Thrombocytopenia	3 (5.8%)	3 (5.8%)	7 (13.5%)	0	5 (15.2%)	0	3 (9.1%)	0	0.793
Anemia	14 (26.9%)	0	1 (19.2%)	0	9 (27.3%)	0	1 (3%)	0	0.869
Febrile neutropenia/infections	12 (23.1%)	2 (3.8%)	1 (1.9%)	1 (1.9%)	7 (21.2%)	1 (3%)	2 (6.1%)	1 (3%)	0.716
Hepatotoxicity	12 (23.1%)	2 (3.8%)	0	0	10 (30%)	2 (6.1%)	0	0	0.355
Nephrotoxicity	4 (7.7%)	0	0	0	1 (3%)	0	0	0	0.382
Coagulopathy/DVT	7 (13.5%)	0	0	1 (1.9%)	0	0	0	0	0.02
Gastrointestinal	0	1 (1.9%)	0	0	6 (18.2%)	0	0	0	0.01
Mucositis	6 (11.5%)	1 (1.9%)	1 (1.9%)	0	1 (3%)	0	0	0	0.07
Acute neurotoxicity	0	0	1 (1.9%)	1 (1.9%)	1 (3%)	0	0	0	0.832

The worst toxicity per organ, per patient, was considered for analyses. DVT, Deep-vein thrombosis (including pulmonary embolism)

ISSN: 1471-2407